Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.


Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
11 2021
Historique:
received: 27 10 2020
revised: 20 05 2021
accepted: 21 05 2021
pubmed: 13 6 2021
medline: 9 2 2022
entrez: 12 6 2021
Statut: ppublish

Résumé

Alcohol is the most common cause of liver-related mortality and morbidity. We therefore aimed to assess and compare the prognostic performance of elastography and blood-based markers to predict time to the first liver-related event, severe infection, and all-cause mortality in patients with a history of excess drinking. We performed a prospective cohort study in patients with early, compensated alcohol-related liver disease. At baseline, we obtained a liver biopsy, transient elastography (TE), 2-dimensional shear-wave elastography (2D-SWE), enhanced liver fibrosis test (ELF), FibroTest, fibrosis-4 index (FIB-4), non-alcoholic fatty liver fibrosis score (NFS) and Forns index. We compared C-statistics and time-dependent AUC for prognostication. We used validated cut-off points to create 3 risk groups for each test: low, intermediate and high risk. We followed 462 patients for a median of 49 months (IQR 31-70). Median age was 57 years, 76% were males, 20% had advanced fibrosis. Eighty-four patients (18%) developed a liver-related event after a median of 18 months (7-34). TE had the highest prognostic accuracy, with a C-statistic of 0.876, and time-dependent AUC at 5 years of 0.889, comparable to 2D-SWE and ELF. TE, ELF and 2D-SWE outperformed FibroTest, FIB4, NFS, Forns index and biopsy-verified fibrosis stage. Compared to patients with TE <10 kPa, the hazard ratios for liver-related events for TE 10-15 kPa were 8.1 (3.2-20.4), and 27.9 (13.8-56.8) for TE >15 kPa. Periods of excessive drinking during follow-up increased the risk of progressing to liver-related events, except for patients in the low-risk groups. TE, ELF and 2D-SWE are highly accurate prognostic markers in patients with alcohol-related liver disease. Easy-to-use cut-offs can distinguish between substantially different risk profiles. Alcohol is the leading cause of death and illness due to liver disease. In this study, we assessed the ability of biomarkers to predict the risk of developing symptomatic liver disease in patients with early stages of alcohol-related liver disease. We found that several tests accurately predicted the risk of liver-related events such as ascites, esophageal varices and hepatic encephalopathy during an average follow-up of 4.1 years. Liver stiffness measurements by ultrasound elastography and the enhanced liver fibrosis test performed best. By using them, we were able to stratify patients into 3 groups with significantly different risks.

Sections du résumé

BACKGROUND & AIMS
Alcohol is the most common cause of liver-related mortality and morbidity. We therefore aimed to assess and compare the prognostic performance of elastography and blood-based markers to predict time to the first liver-related event, severe infection, and all-cause mortality in patients with a history of excess drinking.
METHODS
We performed a prospective cohort study in patients with early, compensated alcohol-related liver disease. At baseline, we obtained a liver biopsy, transient elastography (TE), 2-dimensional shear-wave elastography (2D-SWE), enhanced liver fibrosis test (ELF), FibroTest, fibrosis-4 index (FIB-4), non-alcoholic fatty liver fibrosis score (NFS) and Forns index. We compared C-statistics and time-dependent AUC for prognostication. We used validated cut-off points to create 3 risk groups for each test: low, intermediate and high risk.
RESULTS
We followed 462 patients for a median of 49 months (IQR 31-70). Median age was 57 years, 76% were males, 20% had advanced fibrosis. Eighty-four patients (18%) developed a liver-related event after a median of 18 months (7-34). TE had the highest prognostic accuracy, with a C-statistic of 0.876, and time-dependent AUC at 5 years of 0.889, comparable to 2D-SWE and ELF. TE, ELF and 2D-SWE outperformed FibroTest, FIB4, NFS, Forns index and biopsy-verified fibrosis stage. Compared to patients with TE <10 kPa, the hazard ratios for liver-related events for TE 10-15 kPa were 8.1 (3.2-20.4), and 27.9 (13.8-56.8) for TE >15 kPa. Periods of excessive drinking during follow-up increased the risk of progressing to liver-related events, except for patients in the low-risk groups.
CONCLUSION
TE, ELF and 2D-SWE are highly accurate prognostic markers in patients with alcohol-related liver disease. Easy-to-use cut-offs can distinguish between substantially different risk profiles.
LAY SUMMARY
Alcohol is the leading cause of death and illness due to liver disease. In this study, we assessed the ability of biomarkers to predict the risk of developing symptomatic liver disease in patients with early stages of alcohol-related liver disease. We found that several tests accurately predicted the risk of liver-related events such as ascites, esophageal varices and hepatic encephalopathy during an average follow-up of 4.1 years. Liver stiffness measurements by ultrasound elastography and the enhanced liver fibrosis test performed best. By using them, we were able to stratify patients into 3 groups with significantly different risks.

Identifiants

pubmed: 34118335
pii: S0168-8278(21)00411-6
doi: 10.1016/j.jhep.2021.05.037
pmc: PMC8522804
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1017-1025

Investigateurs

Ema Anastasiadou (E)
Manimozhian Arumugam (M)
Peer Bork (P)
Torben Hansen (T)
Christina Hartoft (C)
Hans Israelsen (H)
Morten Karsdal (M)
Cristina Legido-Quigley (C)
Hans Olav Melberg (HO)
Maja Thiele (M)
Jonel Trebicka (J)
Aleksander Krag (A)
Peer Bork (P)
Mathias Mann (M)
Jelle Matthijnssens (J)
Aleksander Krag (A)
Torben Hansen (T)

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest Aleksander Krag: Speakers fee and advisory board for Siemens Healthcare. Maja Thiele: Speakers fee for Echosens and Siemens Healthcare. Steen Antonsen: Speakers fee for Siemens Healthcare. Other authors: None. Please refer to the accompanying ICMJE disclosure forms for further details.

Références

PLoS One. 2012;7(5):e36676
pubmed: 22574212
JAMA. 1982 May 14;247(18):2543-6
pubmed: 7069920
BMJ. 2016 Sep 07;354:i4428
pubmed: 27605111
Gastroenterology. 2020 Jan;158(1):200-214
pubmed: 31563624
Clin Chem. 2006 Oct;52(10):1887-96
pubmed: 16931569
Gastroenterology. 2016 Jan;150(1):123-33
pubmed: 26435270
J Gastroenterol Hepatol. 2021 Jun;36(6):1435-1449
pubmed: 33171534
J Hepatol. 2017 Mar;66(3):610-618
pubmed: 27894795
Hepatology. 2008 Nov;48(5):1549-57
pubmed: 18846542
Ultraschall Med. 2017 Aug;38(4):e16-e47
pubmed: 28407655
Hepatology. 2011 Mar;53(3):810-20
pubmed: 21319198
Scand J Gastroenterol. 2019 Mar;54(3):328-334
pubmed: 30907181
J Hepatol. 2014 Feb;60(2):282-9
pubmed: 24128415
PLoS One. 2015 Jun 17;10(6):e0128774
pubmed: 26083565
Clin Infect Dis. 2015 Mar 15;60(6):950-8
pubmed: 25422386
Gastroenterology. 2013 Oct;145(4):782-9.e4
pubmed: 23860502
J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e86-e94
pubmed: 30570529
Gut. 2010 Sep;59(9):1245-51
pubmed: 20675693
Gastroenterology. 2018 Oct;155(4):1154-1163.e3
pubmed: 30009816
Hepatology. 2014 Dec;60(6):1911-9
pubmed: 25142433
PLoS One. 2014 Apr 22;9(4):e95776
pubmed: 24755824
Liver Int. 2015 Jun;35(6):1673-81
pubmed: 25495373
Hepatology. 2002 Oct;36(4 Pt 1):986-92
pubmed: 12297848
Lancet Gastroenterol Hepatol. 2018 Sep;3(9):614-625
pubmed: 29983372
Hepatology. 2009 Jan;49(1):97-105
pubmed: 19053048
Aliment Pharmacol Ther. 2014 Jul;40(2):178-88
pubmed: 24889599
Hepatology. 2007 Apr;45(4):846-54
pubmed: 17393509
J Hepatol. 2021 May;74(5):1109-1116
pubmed: 33307138
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
Gastroenterology. 2018 Apr;154(5):1369-1379
pubmed: 29317276
Am J Gastroenterol. 2017 May;112(5):740-751
pubmed: 27725647
Liver Int. 2016 Mar;36(3):370-7
pubmed: 26104018
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
Croat Med J. 2015 Oct;56(5):470-81
pubmed: 26526884

Auteurs

Ditlev Nytoft Rasmussen (DN)

Department of Gastroenterology and Hepatology, Odense University Hospital, Denmark; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

Maja Thiele (M)

Department of Gastroenterology and Hepatology, Odense University Hospital, Denmark; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. Electronic address: maja.thiele@rsyd.dk.

Stine Johansen (S)

Department of Gastroenterology and Hepatology, Odense University Hospital, Denmark; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

Maria Kjærgaard (M)

Department of Gastroenterology and Hepatology, Odense University Hospital, Denmark.

Katrine Prier Lindvig (KP)

Department of Gastroenterology and Hepatology, Odense University Hospital, Denmark; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

Mads Israelsen (M)

Department of Gastroenterology and Hepatology, Odense University Hospital, Denmark.

Steen Antonsen (S)

Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark; Department of Clinical Biochemistry, Odense University Hospital Svendborg, Denmark.

Sönke Detlefsen (S)

Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark; Department of Pathology, Odense University Hospital, Denmark.

Aleksander Krag (A)

Department of Gastroenterology and Hepatology, Odense University Hospital, Denmark; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH